Federal Register Notice: FDA and NIH will co-sponsor a public scientific workshop 3/20 to discuss dystrophin protein quantification methodologies for human tissue. Its purpose is to discuss currently available methodologies and to identify scientific knowledge gaps and opportunities for improving dystrophin protein detection in the context of drug development. The intended audiences are scientists and clinicians involved in the acquisition, measurement, and analysis of proteins associated with Duchenne Muscular Dystrophy (DMD). The workshop will be held from 8:30 a.m. to 5:30 p.m. at FDA’s White Oak Campus, 10903 New Hampshire Ave., Bldg. 31 Conference Center, the Great Room (Rm. 1503A), Silver Spring, MD. Contact Mary Gross, mary.gross@fda.hhs.gov or Georgiann Ienzi, georgiann.ienzi@fda.hhs.gov. To view this notice, click here.